MGTX · MeiraGTx Holdings plc

On April 20, 2026, MeiraGTx Holdings plc and affiliates achieved the initial closing of a major strategic collaboration with Hologen Limited and its affiliates, marking a pivotal advancement in their gene therapy pipeline. This involved amendments to two pre-existing Framework Agreements from March 9, 2025—one for neuro programs via Hologen Neuro AI Limited (HNAI) and one for manufacturing via MeiraGTx Manufacturing Limited—plus a new Collaboration and License Agreement. The transaction builds on Hologen's prior $105 million payments toward a $200 million upfront commitment, with the balance to fund post-completion share purchases. In HNAI, Hologen will secure 70% ownership through Class B shares post-completion, while MeiraGTx Neuro UK retains 30% Class A shares, aligning interests in developing AAV-GAD for Parkinson’s disease, AAV-BDNF for genetic obesity disorders, additional CNS-targeted genetic medicines, and a proprietary delivery device for local gene therapy administration. For manufacturing, Hologen gains a minority stake via pre- and post-completion share acquisitions from MeiraGTx Limited, plus an exclusive option to reach 40% within 12 months of the additional purchase closing; MeiraGTx holds a reciprocal call option exercisable from the third anniversary. These structures provide Hologen significant equity participation and control in key entities driving the programs, while MeiraGTx retains meaningful stakes and strategic options. Completion remains subject to conditions including foreign investment clearances, with full agreements detailed in Exhibits 10.1-10.3. This partnership enhances funding and expertise for MeiraGTx’s clinical programs, potentially accelerating development and commercialization amid biotech funding challenges.